Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation
نویسندگان
چکیده
منابع مشابه
Outcomes after 90Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are chemosensitive. The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) is commonly used as a conditioning regimen. The addition of yttrium-90 ((90) Y)-ibritumomab tiuxetan (Zevalin(®)) to BEAM ...
متن کاملOutcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.
BACKGROUND The proportion of potentially eligible patients with transformed indolent non-Hodgkin lymphoma who undergo autologous stem-cell transplantation (ASCT) is unknown. There are limited data describing their outcome in the rituximab era. PATIENTS AND METHODS We reviewed 105 consecutive patients with biopsy-proven transformation referred to Princess Margaret Hospital for consideration of...
متن کاملRadioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
The clinical development and US Food and Drug Administration approval in 1997 of the monoclonal anti-CD20 antibody rituximab have been major treatment advances for patients with B-cell non-Hodgkin's lymphoma (NHL). Rituximab produces responses in approximately 50% of cases of relapsed, low grade NHL. Most of these responses are partial remissions; cure remains elusive. One way to enhance the ef...
متن کاملTITLE : High dose Y - 90 - Ibritumomab - Tiuxetan with autologous stem cell transplantation in refractory - resistant NHL
BODY: Objectives : Therapeutic options are limited for aggressive high-grade NHL pts not suitable to high dose chemotherapy. Y-90-Ibritumomab-Tiuxetan has already been demonstrated active in elderly pts with resistantrefractory DLBCL at standard activity, however response is usually of short duration. Increasing RIT dose-intensity could improve and prolong efficacy. We evaluated feasibility and...
متن کاملReturn to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation
BACKGROUND Autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed diffuse large B-cell lymphoma (DLBCL) or transformed indolent lymphoma (TIL). The treatment is mainly considered for younger patients still available for the work market. In this study, social outcomes after ASCT in terms of return to work (RTW) are described. PATIENTS AND METHODS Infor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2012
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2011.08991.x